Medtronic PLC $MDT Shares Purchased by CORDA Investment Management LLC.

Key Points

• CORDA Investment Management increased its Medtronic stake by 9% in the second quarter, acquiring 24,604 shares for a total holding of 296,967 shares valued at approximately $23.2 million. Institutional investors collectively own 82.06% of the company.
• Medtronic exceeded quarterly earnings and revenue expectations, reporting $1.55 in EPS and $9.81 billion in revenue, up 9.9% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $98.83.
• The company raised its quarterly dividend to $0.72 per share, or $2.88 annually, yielding about 3.1%; Medtronic has increased its dividend for 49 consecutive years. Risks include recent insider selling and a potential injunction related to its Applied Medical case.

CORDA Investment Management LLC. raised its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 9.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 296,967 shares of the medical technology company's stock after acquiring an additional 24,604 shares during the quarter. Medtronic makes up 1.4% of CORDA Investment Management LLC.'s investment portfolio, making the stock its 28th largest position. CORDA Investment Management LLC.'s holdings in Medtronic were worth $23,232,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Sandro Wealth Management LLC lifted its holdings in shares of Medtronic by 18.3% in the second quarter. Sandro Wealth Management LLC now owns 5,691 shares of the medical technology company's stock valued at $445,000 after purchasing an additional 879 shares in the last quarter. Focus Partners Advisor Solutions LLC raised its position in shares of Medtronic by 31.5% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 15,629 shares of the medical technology company's stock worth $1,223,000 after purchasing an additional 3,747 shares during the last quarter. State of Wyoming lifted its stake in Medtronic by 120.0% in the 2nd quarter. State of Wyoming now owns 4,727 shares of the medical technology company's stock valued at $370,000 after buying an additional 2,578 shares in the last quarter. Kelleher Financial Advisors lifted its stake in Medtronic by 64.5% in the 2nd quarter. Kelleher Financial Advisors now owns 2,179 shares of the medical technology company's stock valued at $170,000 after buying an additional 854 shares in the last quarter. Finally, GSA Capital Partners LLP grew its holdings in Medtronic by 1,112.5% during the 2nd quarter. GSA Capital Partners LLP now owns 68,541 shares of the medical technology company's stock valued at $5,362,000 after buying an additional 62,888 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Insider Activity

In related news, EVP Harry Skip Kiil sold 4,189 shares of the firm's stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president directly owned 37,227 shares of the company's stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.26% of the company's stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Bank of America issued a bullish outlook ahead of earnings. The firm sees continued momentum from one of Medtronic’s key growth businesses and believes an additional catalyst could develop, potentially improving investor expectations before the results. Bank of America makes bullish call on 77-year-old healthcare stock
• Positive Sentiment: Medtronic is one dividend increase away from Dividend King status. The company has raised its dividend for 49 consecutive years and currently pays $0.72 per quarter, or $2.88 annually. Reaching the 50-year milestone could reinforce MDT’s appeal to income-focused and defensive investors. Medtronic plc is Closing in on Dividend King Status
• Neutral Sentiment: BTIG reaffirmed its “Buy” rating but set a $91 price target, below MDT’s recent trading level. The recommendation supports the long-term outlook, while the target suggests limited near-term upside at current levels. Other recent analyst targets have been mixed, with a reported median of $101. BTIG reaffirms buy rating on Medtronic
• Neutral Sentiment: Value-investor comparisons with Agilent Technologies and proxy-recommendation coverage may attract attention, but neither provides a clear new earnings or fundamental catalyst for MDT. MDT vs. A: Which Stock Should Value Investors Buy Now?
• Negative Sentiment: Medtronic faces a potential injunction in its Applied Medical case. An adverse ruling could create operational or legal uncertainty and represents a risk ahead of earnings. Medtronic faces potential injunction in Applied Medical case
• Negative Sentiment: Reported insider activity showed eight sales and no purchases over the past six months, while estimated CEO compensation increased year over year. These signals could weigh modestly on sentiment, although they do not necessarily indicate a change in Medtronic’s fundamentals. Medtronic CEO 2026 Pay Revealed

Analysts Set New Price Targets

Several equities analysts have weighed in on MDT shares. Leerink Partners dropped their price target on Medtronic from $117.00 to $104.00 and set an "outperform" rating for the company in a research report on Thursday, June 4th. Rothschild & Co Redburn dropped their price objective on Medtronic from $111.00 to $106.00 and set a "buy" rating for the company in a research report on Friday, June 5th. Piper Sandler reissued a "neutral" rating on shares of Medtronic in a research note on Monday, August 10th. Stifel Nicolaus set a $80.00 target price on shares of Medtronic in a report on Wednesday, June 3rd. Finally, Robert W. Baird decreased their price target on shares of Medtronic from $93.00 to $85.00 and set a "neutral" rating on the stock in a research note on Thursday, June 4th. Eighteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.83.

Medtronic Price Performance

Shares of NYSE:MDT opened at $94.13 on Thursday. The company has a market cap of $120.49 billion, a P/E ratio of 25.24, a P/E/G ratio of 2.47 and a beta of 0.55. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The business has a fifty day simple moving average of $83.88 and a 200-day simple moving average of $86.08.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same period in the prior year, the business posted $1.62 earnings per share. The firm's revenue for the quarter was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts forecast that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date was Friday, June 26th. This is an increase from Medtronic's previous quarterly dividend of $0.71. Medtronic's payout ratio is currently 77.21%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source